RE: RE: Pet scan delays...
Yup management could off taken the offer and it would have been a friendly take over.
I think they are as annoyed as all the disgrunted shareholders about market valuation.
Shigamabs has fast track and orphan drug status. Whatever the market size for E.Coli, TLN has 100% of it for the 8-10 years after approval. The longest protection ever.
Also, 232 mecanism of action is novel and potentially very promissing
4601 has the ability to target mutated PBR cell, no other cancerous drug has that ability.
Threshold for approval is quite low for both drug candidate, efficacy for more than 5% of the population on a replicable scale is sufficient to get regulatory approval.